The historical rank and industry rank for Vanda Pharmaceuticals's Net Margin % or its related term are showing as below:
LTS:0LKB'
s Net Margin % Range Over the Past 10 Years
Min: -109.99 Med: 1.89 Max: 50.86
Current: -109.99
LTS:0LKB's Net Margin % is ranked worse than 51.95% of 947
companies
in the Biotechnology industry
Industry Median: -89.56
vs LTS:0LKB: -109.99
Vanda Pharmaceuticals (LTS:0LKB) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Vanda Pharmaceuticals Net Margin % Related Terms
Vanda Pharmaceuticals Net Margin % Historical Data
* Premium members only.
The historical data trend for Vanda Pharmaceuticals's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0LKB vs FBRX, ARTV, OABI: Net Margin % Comparison
For the Biotechnology subindustry, Vanda Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vanda Pharmaceuticals Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Vanda Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vanda Pharmaceuticals (LTS:0LKB) has a Net Margin % of -93.91% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Vanda Pharmaceuticals and its competitors. According to the industry distribution chart, Vanda Pharmaceuticals ranks #492 out of 947 companies in the Biotechnology industry, placing it in the top 52%.
Is Vanda Pharmaceuticals' Net Margin % too high?
Vanda Pharmaceuticals' current Net Margin % is -93.91%. Based on the distribution chart, Vanda Pharmaceuticals ranks #492 out of 947 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vanda Pharmaceuticals has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vanda Pharmaceuticals' Net Margin % compare to FBRX and ARTV?
According to the Biotechnology industry distribution chart, Vanda Pharmaceuticals ranks #492 out of 947 companies for Net Margin %. This places Vanda Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Vanda Pharmaceuticals and its competitors. Vanda Pharmaceuticals's current Net Margin % is -93.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vanda Pharmaceuticals (LTS:0LKB) is currently considered Fairly Valued. The stock's GF Value™ is $5.57, compared to a current price of $5.91 — trading 6.1% above its estimated fair value. The current Net Margin % is -93.91%. Vanda Pharmaceuticals' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Vanda Pharmaceuticals (LTS:0LKB), the current Net Margin % is -93.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vanda Pharmaceuticals (LTS:0LKB) Overvalued in 2026?
Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be overvalued.
The current stock price of $5.91 is trading 6.1% above its estimated GF Value™ of $5.57.
GuruFocus considers Vanda Pharmaceuticals to be Fairly Valued.
Key valuation signals for LTS:0LKB:
Net Margin %: -93.91%
GF Value™: $5.57 vs. price of $5.91 (6.1% above fair value)
No single metric tells the full story. See the LTS:0LKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
71GF Score
Get the complete analysis for LTS:0LKB
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0LKB has been successfully added to your 
